BETHESDA — Cancer drug developer Micromet Inc. on Tuesday named Ulrich Grau, a biopharmaceutical industry veteran, as its executive vice president and chief operating officer, effective immediately.
Grau has more than 30 years of experience in operations and research and development at biotechnology and pharmaceutical companies.
Grau most recently served as president and CEO of Lux Biosciences Inc., a clinical stage private ophthalmic company that he co-founded.
Previously, he worked at such companies as BASF Pharma/Knoll, Aventis Pharma and Hoechst Marion Roussel.
Micromet’s lead product candidate is the potential cancer treatment blinatumomab.
Shares of Micromet rose 2 cents to $5.48 in late morning trading.